摘要
目的观察且分析重组人血管内皮抑制素注射液联合FOLFOX方案在晚期胃癌临床治疗中的效果。方法选取本院在2014年7月~2015年7月所收治的晚期胃癌患者46例作为临床对象,随机分成对照组、观察组。对照组予以FOLFOX方案进行治疗,观察组予以重组人血管内皮抑制素注射液联合FOLFOX方案进行治疗,观察与比较两组临床疗效。结果经过实施不同的治疗方案之后,观察组在临床治疗中的总有效率（69.57%）比对照组（39.13%）高,且经统计学分析,P〈0.05,差异有统计学意义。但是两组的不良反应经对比,差异无统计学意义,P〉0.05。结论对晚期胃癌的临床患者予以重组人血管内皮抑制素注射液联合FOLFOX方案进行治疗,治疗有效率提升,具有较好的安全性。
Objective To observe and analyze human recombinant endostatin injection combined FOLFOX scheme in the treatment of advanced gastric cancer clinical effect. Methods 46 cases patients with advanced gastric cancer treated were chosen as clinical subject in our hospital from July 2014 to July 2015, randomly divided into control group and observation group. Control group to be FOLFOX solution treatment, observation group to human recombinant endostatin injection combined FOLFOX scheme for treatment, observation and comparison of two groups of clinical curative effect. Results After implement different treatment, the observation group in the clinical treatment of total effective rate（69.57%） was higher than the control group（39.13%）, and the statistical analysis, P〈0.05, the difference was statistically significant. But the two groups of adverse reactions by contrast, there was no statistically significant difference, P〉0.05. Conclusion In patients with advanced gastric cancer clinical human recombinant endostatin injection combined FOLFOX scheme for treatment, treatment effectiveness, has good safety.
出处
《中国继续医学教育》
2016年第36期103-104,共2页
China Continuing Medical Education
